Clinical trials: Severe Psoriasis
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Psoriasis
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03835481
- Testing
- BI 730357
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 165 people
- Sponsor
- Boehringer Ingelheim
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate to Severe Plaque Psoriasis
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE CONNECTED (NCT04718896)
- Testing
- bimekizumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
- Trial name
- Ixora-peds (NCT03073200)
- Testing
- Ixekizumab, Etanercept
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Candidates for Systemic Therapy for Psoriasis, Psoriasis
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.
- Trial name
- NCT00287118
- Testing
- Efalizumab
- Where
- Switzerland
- Volunteers
- 189 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis.
- Trial name
- EMBRACE 1 (NCT04305327)
- Testing
- Brodalumab, Ustekinumab
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 12 people
- Sponsor
- LEO Pharma
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Scalp Psoriasis
Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study
- Trial name
- NCT02932462
- Testing
- DSXS
- Volunteers
- 373 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral…
- Trial name
- NCT02576678
- Testing
- Apremilast
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 42 people
- Sponsor
- Amgen
Plaque Psoriasis
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
- Trial name
- NCT02527421
- Testing
- DFD01 Spray
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Primus Pharmaceuticals
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-1 (NCT04435600)
- Testing
- Risankizumab, Ustekinumab
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Chronic Severe Plaque-type Psoriasis
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis.
- Trial name
- NCT02471144
- Testing
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Active Comparator: Etanercept
- Where
- 46 sites in United States, Belgium and 17 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis
- Trial name
- CADMUS Jr (NCT02698475)
- Testing
- Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC